{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:30:31Z","timestamp":1790209831004,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejmech.2021.114035","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T19:27:48Z","timestamp":1638905268000},"page":"114035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs"],"prefix":"10.1016","volume":"228","author":[{"given":"Xiaoan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9006-8820","authenticated-orcid":false,"given":"Tiantian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6235-7687","authenticated-orcid":false,"given":"Shaoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8493-5812","authenticated-orcid":false,"given":"Yongmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.114035_bib1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019","volume":"76","author":"Roth","year":"2020","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2021.114035_bib2","first-page":"785","article-title":"The progress about the clinical application of antithrombotic agents","volume":"21","author":"Hu","year":"2017","journal-title":"Anhui Med. Pharma. J."},{"key":"10.1016\/j.ejmech.2021.114035_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14728222.6.2.159","article-title":"Tissue factor - a therapeutic target for thrombotic disorders","volume":"6","author":"Houston","year":"2002","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2021.114035_bib4","first-page":"793","article-title":"The mechanism of thrombosis","volume":"21","author":"Li","year":"2004","journal-title":"J.Clin. Inter. Med."},{"key":"10.1016\/j.ejmech.2021.114035_bib5","first-page":"25","article-title":"Mechanism of thrombosis and pharmacological characteristics of anticoagulant drugs, Chin","volume":"13","author":"Ji","year":"2021","journal-title":"J.\u00a0Fami. Plan. & Gyne."},{"key":"10.1016\/j.ejmech.2021.114035_bib6","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1039\/C4NP00076E","article-title":"Chemoenzymatic synthesis of heparan sulfate and heparin","volume":"31","author":"Liu","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2021.114035_bib7","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1021\/jacs.7b01923","article-title":"Synthesis of 3-o-sulfated oligosaccharides to understand the relationship between structures and functions of heparan sulfate","volume":"139","author":"Wang","year":"2017","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.114035_bib8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.bmc.2003.12.039","article-title":"Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa)","volume":"12","author":"Polla","year":"2004","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1055\/s-2002-34309","article-title":"The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa","volume":"28","author":"Petitou","year":"2002","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ejmech.2021.114035_bib10","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1016\/j.bmc.2019.06.033","article-title":"Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids","volume":"27","author":"Singh","year":"2019","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib11","first-page":"185","article-title":"Pharmacological action and clinical application of agatroban","volume":"13","author":"Luo","year":"2007","journal-title":"Chin. J. Throm. Hemost."},{"key":"10.1016\/j.ejmech.2021.114035_bib12","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1021\/jm901743x","article-title":"Leech-derived thrombin inhibitors: from structures to mechanisms to clinical applications","volume":"53","author":"Corral-Rodr\u00edguez","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1744-9081-10-42","article-title":"Time course change of COX2-PGI2\/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus","volume":"10","author":"Yu","year":"2014","journal-title":"Behav. Brain Funct."},{"key":"10.1016\/j.ejmech.2021.114035_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.abb.2008.09.010","article-title":"Large-scale expression, purification, and characterization of an engineered prostacyclin-synthesizing enzyme with therapeutic potential","volume":"480","author":"Ruan","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2021.114035_bib15","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1021\/jm9701076","article-title":"Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa","volume":"40","author":"Fisher","year":"1997","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib16","first-page":"58","article-title":"The application of platelet glycoprotein \u2161 b\/\u2162 a receptor antagonist in cerebral arterial thrombosis","volume":"16","author":"Zhang","year":"2009","journal-title":"Stroke Ner. Dis."},{"key":"10.1016\/j.ejmech.2021.114035_bib17","first-page":"169","article-title":"The mechanism of thrombus and the zdvances in research of thrombolitics","volume":"27","author":"Lu","year":"2006","journal-title":"Food Res. Dev."},{"key":"10.1016\/j.ejmech.2021.114035_bib18","first-page":"672","article-title":"Advances of antithrombotic agents in clinical application","volume":"37","author":"Tang","year":"2016","journal-title":"Adv. Cardiovas. Dis."},{"key":"10.1016\/j.ejmech.2021.114035_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bioorg.2013.11.002","article-title":"New series of 6-substituted coumarin derivatives as effective factor Xa inhibitors: synthesis, in\u00a0vivo antithrombotic evaluation and molecular docking","volume":"52","author":"Amin","year":"2014","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.bjp.0701566","article-title":"Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time","volume":"123","author":"Sato","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114035_bib21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1055\/s-0037-1615078","article-title":"Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis","volume":"79","author":"Kawasaki","year":"1998","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2021.114035_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijbiomac.2018.07.048","article-title":"Antithrombotic potential of esculin 7, 3', 4', 5', 6'-O-pentasulfate (EPS) for its role in thrombus reduction using rat thrombosis model","volume":"119","author":"Irshad","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2021.114035_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11094-019-02013-z","article-title":"Synthesis and in\u00a0vivo evaluation of new coumarin conjugates as potential indirect-action anticoagulants","volume":"53","author":"Bang","year":"2019","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.ejmech.2021.114035_bib24","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.pharep.2018.06.002","article-title":"A\u00a0biological, fluorescence and computational examination of synthetic coumarin derivatives with antithrombotic potential","volume":"6","author":"Kasperkiewicz","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2021.114035_bib25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejmech.2012.04.044","article-title":"Metabolism-based synthesis, biologic evaluation and SARs analysis of o-methylated analogs of quercetin as thrombin inhibitors","volume":"54","author":"Shi","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejmech.2015.04.012","article-title":"Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors","volume":"96","author":"Li","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ardp.201400463","article-title":"Synthesis and biological evaluation of some new 2,5-Substituted 1-ethyl-1H-benzoimidazole fluorinated derivatives as direct thrombin inhibitors","volume":"348","author":"Li","year":"2015","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2021.114035_bib28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ardp.201400460","article-title":"Design, synthesis, and anti-thrombotic evaluation of some novel fluorinated thrombin inhibitor derivatives","volume":"348","author":"Chen","year":"2015","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2021.114035_bib29","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1016\/j.bmc.2015.10.036","article-title":"Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors","volume":"23","author":"Chen","year":"2015","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejmech.2016.05.020","article-title":"Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives","volume":"120","author":"Ren","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib31","series-title":"Heparin - a Century of Progress","author":"Lever","year":"2012"},{"key":"10.1016\/j.ejmech.2021.114035_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-23056-1_1","article-title":"History of Heparin","author":"Barrowcliffe","year":"2012"},{"key":"10.1016\/j.ejmech.2021.114035_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0008-6215(01)00270-1","article-title":"Generation of anti-factor Xa active, 3-O-sulfated glucosamine-rich sequences by controlled desulfation of oversulfated heparins","volume":"336","author":"Naggi","year":"2001","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2021.114035_bib34","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1021\/jm051221o","article-title":"Heparin derivatives as inhibitors of BACE-1, the alzheimer's \u03b2-secretase, with reduced activity against factor Xa and other proteases","volume":"49","author":"Patey","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.carbpol.2016.03.061","article-title":"Optimization of chemical sulfation, structural characterization and anticoagulant activity of Agaricus bisporus fucogalactan","volume":"146","author":"Roman","year":"2016","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejmech.2021.114035_bib36","doi-asserted-by":"crossref","first-page":"41278","DOI":"10.1074\/jbc.M501124200","article-title":"Structural and hemostatic activities of a sulfated galactofucan from the brown alga Spatoglossum schroederi. an ideal antithrombotic agent?","volume":"280","author":"Rocha","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib37","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.ijbiomac.2018.06.143","article-title":"Anti-IIa activity and antitumor properties of a hybrid heparin\/heparan sulfate-like compound from Litopenaeus vannamei shrimp","volume":"118","author":"Brito","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2021.114035_bib38","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1021\/jm00059a015","article-title":"Glycosylated derivatives of benzophenone, benzhydrol and benzhydril as potential venous antithrombotic agents","volume":"36","author":"Bellamy","year":"1993","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0008-6215(97)00001-3","article-title":"Synthesis of 4-cyanophenyl 2-deoxy-1,5-dithio-\u03b2-d-threo-pentopyranoside","volume":"299","author":"Boz\u00f3","year":"1997","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2021.114035_bib40","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.carres.2011.03.037","article-title":"Selective carboxypropionylation of chitosan: synthesis, characterization, blood compatibility, and degradation","volume":"346","author":"Xiong","year":"2011","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2021.114035_bib41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0008-6215(98)00221-3","article-title":"Synthesis of 4-cyanophenyl and 4-nitrophenyl 1,5-dithio-l- and -d-arabinopyranosides possessing antithrombotic activity","volume":"311","author":"Boz\u00f3","year":"1998","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2021.114035_bib42","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/cbdd.12204","article-title":"Improving the thrombin inhibitory activity of glycyrrhizin, a triterpenic saponin, through a molecular simplification of the carbohydrate moiety","volume":"82","author":"de Paula","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2021.114035_bib43","doi-asserted-by":"crossref","first-page":"111722","DOI":"10.1016\/j.ejmech.2019.111722","article-title":"Discovery of novel, potent, isosteviol-based antithrombotic agents","volume":"183","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib44","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/S0968-0896(02)00106-2","article-title":"Design, synthesis and biological activity of YM-60828 derivatives: potent and orally bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates","volume":"10","author":"Hirayama","year":"2002","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/s-0037-1614941","article-title":"Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa","volume":"79","author":"Taniuchi","year":"1998","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2021.114035_bib46","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/S0968-0896(02)00106-2","article-title":"Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates","volume":"10","author":"Hirayama","year":"2002","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0968-0896(02)00462-5","article-title":"Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template","volume":"11","author":"Hirayama","year":"2003","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib48","series-title":"Inventors. New 4-aminopridines,process for Preparing the Same and Medicaments Containing the Same","author":"Wolfgang","year":"1994"},{"key":"10.1016\/j.ejmech.2021.114035_bib49","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0960-894X(98)00290-X","article-title":"In\u00a0vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors","volume":"8","author":"Lu","year":"1998","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114035_bib50","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1016\/j.bmc.2007.03.066","article-title":"Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors","volume":"15","author":"Ishihara","year":"2007","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib51","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1021\/jm048984g","article-title":"Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities","volume":"48","author":"Petra","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib52","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1021\/jm8003448","article-title":"3,4-dihydro-2H-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb\/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function","volume":"51","author":"Janez","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib53","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejmech.2013.01.002","article-title":"Towards dual antithrombotic compounds \u2013 balancing thrombin inhibitory and fibrinogen GPIIb\/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism","volume":"62","author":"Ili\u0107","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib54","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s11696-018-0645-x","article-title":"Design and synthesis of novel 3,4-diaminobenzoyl derivatives as antithrombotic agents with improved solubility","volume":"73","author":"Liu","year":"2018","journal-title":"Chem. Pap."},{"key":"10.1016\/j.ejmech.2021.114035_bib55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2174\/1570163815666180215114732","article-title":"The development of new factor Xa inhibitors based on amide synthesis, Curr","volume":"15","author":"Tarasov","year":"2018","journal-title":"Drug Disc. Technol."},{"key":"10.1016\/j.ejmech.2021.114035_bib56","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/jm9903287","article-title":"Structure-based design of potent, amidine-derived inhibitors of factor Xa: evaluation of selectivity, anticoagulant activity, and antithrombotic activity","volume":"43","author":"Wiley","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib57","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1021\/jm990326m","article-title":"1,2-dibenzamidobenzene inhibitors of human factor Xa","volume":"43","author":"Herron","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib58","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/S0960-894X(03)00398-6","article-title":"Polymer-assisted solution-phase (PASP) parallel synthesis of an alpha-ketothiazole library as tissue factor VIIa inhibitors, Bioorg","volume":"13","author":"South","year":"2003","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114035_bib59","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/S0960-894X(03)00410-4","article-title":"Structure-based drug design of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex","volume":"13","author":"South","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114035_bib60","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ejmech.2015.03.052","article-title":"Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation","volume":"95","author":"Xing","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib61","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejmech.2016.09.055","article-title":"Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors","volume":"125","author":"Xing","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib62","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.1016\/j.bmc.2018.09.012","article-title":"Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors","volume":"26","author":"Xing","year":"2018","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib63","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1021\/jm501045e","article-title":"Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor","volume":"57","author":"Xue","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib64","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1016\/j.bmcl.2015.08.070","article-title":"Molecular modeling studies of [6,6,5] tricyclic fused oxazolidinones as FXa inhibitors using 3D-QSAR, topomer COMFA, molecular docking and molecular dynamics simulations","volume":"25","author":"Xu","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114035_bib65","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bmcl.2014.12.039","article-title":"Design, synthesis and evaluation of isoxazolo[5,4-d]pyrimidin-4(5H)-one derivatives as antithrombotic agents","volume":"25","author":"Yang","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114035_bib66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","article-title":"Factor Xa or thrombin: is factor Xa a better target?","volume":"5","author":"Ansell","year":"2007","journal-title":"J.\u00a0Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2021.114035_bib67","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1016\/j.bmcl.2012.05.046","article-title":"Discovery of benzothiazole guanidines as novel inhibitors of thrombin and trypsin IV, Bioorg","volume":"22","author":"Karle","year":"2012","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114035_bib68","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1016\/j.bmc.2014.09.059","article-title":"Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates","volume":"22","author":"Ishihara","year":"2014","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib69","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J.\u00a0Thromb. Haemostasis"},{"key":"10.1016\/j.ejmech.2021.114035_bib70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00281-011-0288-2","article-title":"The procoagulant and proinflammatory plasma contact system","volume":"34","author":"Renne","year":"2012","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.ejmech.2021.114035_bib71","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejmech.2016.01.023","article-title":"Synthesis, evaluation and structure-activity relationship of new 3-carboxamide coumarins as FXIIa inhibitors","volume":"110","author":"Bouckaert","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib72","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/ml500008w","article-title":"Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar","volume":"5","author":"Chelliah","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114035_bib73","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1016\/j.peptides.2006.04.023","article-title":"The biological activity of the histidine-containing diketopiperazines cyclo(His-Ala) and cyclo(His-Gly)","volume":"27","author":"Lucietto","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.ejmech.2021.114035_bib74","first-page":"1059","article-title":"Design, synthesis and bioactivity of pyrazine skeleton thrombin inhibitors with tetrahydrobenzo [4, 5] midazole and [1, 2-a] pyrazine nucleus","volume":"38","author":"Chen","year":"2017","journal-title":"Chem. J. Chin. Univ."},{"key":"10.1016\/j.ejmech.2021.114035_bib75","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bmcl.2011.11.027","article-title":"Synthesis of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as platelet aggregation inhibitors, Bioorg","volume":"22","author":"Tian","year":"2012","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114035_bib76","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bmcl.2014.02.014","article-title":"The synthesis of 4,7-disubstituted-2H-benzo[b][1,4]-oxazin-3(4H)-ones using Smiles rearrangement and their in\u00a0vitro evaluation as platelet aggregation inhibitors, Bioorg","volume":"24","author":"Xia","year":"2014","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114035_bib77","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3390\/molecules22122081","article-title":"Fluorinated analog NMR s of organosulfur compounds from garlic (Allium sativum): synthesis, chemistry and anti-angiogenesis and antithrombotic studies","volume":"22","author":"Block","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114035_bib78","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/630482","article-title":"Polysulfated trehalose as a novel anticoagulant agent with dual mode of action","volume":"2015","author":"Rashid","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2021.114035_bib79","first-page":"207","article-title":"Lebetin peptides: potent platelet aggregation inhibitors","volume":"31","author":"Marrakchi","year":"2001","journal-title":"Haemostasis"},{"key":"10.1016\/j.ejmech.2021.114035_bib80","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/jm0700971","article-title":"P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring","volume":"50","author":"Costanzi","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0701837","article-title":"Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate","volume":"124","author":"Boyer","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114035_bib82","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/1098-2299(200004)49:4<253::AID-DDR4>3.0.CO;2-1","article-title":"Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors","volume":"49","author":"Brown","year":"2000","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2021.114035_bib83","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/jm0104062","article-title":"Novel antagonists acting at the P2Y(1) purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques","volume":"45","author":"Raboisson","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib84","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1021\/jm010082h","article-title":"Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking","volume":"44","author":"Kim","year":"2001","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib85","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.3390\/molecules20047174","article-title":"Synthesis and antiplatelet activity of antithrombotic thiourea compounds: biological and structure-activity relationship studies","volume":"20","author":"Lourenco","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114035_bib86","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4155\/fmc-2017-0161","article-title":"Design, synthesis and evaluation of 1,4-benzodioxine derivatives as novel platelet aggregation inhibitors","volume":"10","author":"Xie","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib87","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejps.2011.12.001","article-title":"New peptide pENW (pGlu-Asn-Trp) inhibits platelet activation by attenuating Akt phosphorylation","volume":"45","author":"Xiong","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2021.114035_bib88","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejmech.2015.07.016","article-title":"Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp)","volume":"102","author":"Xie","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib89","first-page":"305","article-title":"Synthesis and antiplatelet aggregation activities of prasugrel derivatives","volume":"42","author":"Zhang","year":"2011","journal-title":"J.\u00a0China Pharm. Univ."},{"key":"10.1016\/j.ejmech.2021.114035_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700349","article-title":"Non-peptide-based new class of platelet aggregation inhibitors: design, synthesis, bioevaluation, SAR, and in silico studies","volume":"351","author":"Jaiswal","year":"2018","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2021.114035_bib91","first-page":"32","article-title":"Synthesis and anti-platelet aggregation activities of nicotinic acid derivatives","volume":"21","author":"He","year":"2011","journal-title":"Chin. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib92","first-page":"1403","article-title":"Synthesis and antithrombotic activity of acetylsalicyl p-coumaric acid coupled with furoxans and nitrates","volume":"26","author":"Zhou","year":"2006","journal-title":"Chin. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib93","first-page":"1050","article-title":"Synthesis and antithrombotic activity of acetylsalicyl ferulic acid-coupling furoxans and nitrates","volume":"41","author":"Zhou","year":"2006","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.ejmech.2021.114035_bib94","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1046\/j.1365-2125.1996.00503.x","article-title":"Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study","volume":"42","author":"Milani","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114035_bib95","first-page":"85","article-title":"Synthesis and in\u00a0vitro antiplatelet aggregation activities of 4-methoxy( ethoxy) -1\uff0c3-isophthalamide derivatives, Chin","volume":"24","author":"Wei","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib96","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1016\/j.bmcl.2012.09.001","article-title":"Design, synthesis and in\u00a0vitro activities on anti-platelet aggregation of 4-methoxybenzene-1,3-isophthalamides","volume":"22","author":"Liu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114035_bib97","first-page":"355","article-title":"Synthesis and in\u00a0vitro activity on antiplatelet aggregation of N3-benzhydryl-4-methoxy-1,3-benzenedisulfonamide derivatives, Chin","volume":"27","author":"Deng","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib98","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1399-3011.2003.00062.x","article-title":"Syntheses of cyclic prodrugs of RGD peptidomimetics with various macrocyclic ring sizes: evaluation of physicochemical, transport and antithrombic properties","volume":"61","author":"He","year":"2003","journal-title":"J.\u00a0Pept. Res."},{"key":"10.1016\/j.ejmech.2021.114035_bib99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0045-2068(02)00013-5","article-title":"Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation","volume":"30","author":"Song","year":"2002","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib100","first-page":"819","article-title":"Synthesis and antithrombotic activity of 3-aryl-1,2,3,4-oxatriazole-5-imine-coupled aspirin, Chin","volume":"28","author":"Zhou","year":"2008","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib101","first-page":"345","article-title":"The research progresses of ferulic acid derivatives and its bioactivities","volume":"32","author":"Ma","year":"2008","journal-title":"Prog. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2021.114035_bib102","first-page":"305","article-title":"Synthesis of ferulic acid derivatives and their inhibitory effect on platelet aggregation","volume":"46","author":"Li","year":"2011","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.ejmech.2021.114035_bib103","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1016\/j.bmcl.2007.09.066","article-title":"Structure\u2013activity relationship study on the 6-membered heteroaromatic ring system of diphenylpyrazine-type prostacyclin receptor agonists","volume":"17","author":"Asaki","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114035_bib104","first-page":"698","article-title":"Synthesis of new ((pyrazin-3-yl)methoxy) aryl acid derivatives and their anti-platelet aggregation activities","volume":"29","author":"Ma","year":"2019","journal-title":"Chin. J. Synth. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib105","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1248\/cpb.c14-00330","article-title":"1,4-Benzoxazine-3(4H)-ones as potent inhibitors of platelet aggregation: design, synthesis and structure-activity relations","volume":"62","author":"Liu","year":"2014","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2021.114035_bib106","first-page":"510","article-title":"Synthesis of 6-substituted acylpiperazinylphenyl dihydro pyridazinones and their inhibition of platelet aggregation","volume":"24","author":"Zhao","year":"2003","journal-title":"Acad. J. Second Mil. Med. Univ."},{"key":"10.1016\/j.ejmech.2021.114035_bib107","first-page":"172","article-title":"Synthesis of 6-[4-(substituted piperazinyl) phenyl]-4, 5-hydro-3 (2H) -pyridazinones and their inhibition for platelet aggregation, Chin","volume":"9","author":"Wu","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib108","first-page":"215","article-title":"Synthesis of analogues of pyridazinones and its inhibition on platelet aggregation","volume":"23","author":"Zhao","year":"2002","journal-title":"Acad. J. Second Mil. Med. Univ."},{"key":"10.1016\/j.ejmech.2021.114035_bib109","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/10426507.2013.843003","article-title":"Study of \u201cracemic compound-like\u201d behavior of diastereomeric mixture of pinanyl sulfoxides by X-ray diffraction, IR spectroscopy, and DFT calculations","volume":"189","author":"Startseva","year":"2014","journal-title":"Phosphorus Sulfur"},{"key":"10.1016\/j.ejmech.2021.114035_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00116","article-title":"Sulfur-containing monoterpenoids as potential antithrombotic drugs: research in the molecular mechanism of coagulation activity using pinanyl sulfoxide as an example","volume":"9","author":"Nikitina","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114035_bib111","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1021\/jm0611511","volume":"50","author":"Roma","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib112","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1021\/acs.jmedchem.5b00865","article-title":"Design, virtual screening, and synthesis of antagonists of \u03b1IIb\u03b23 as antiplatelet agents","volume":"58","author":"Polishchuk","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib113","first-page":"586","article-title":"Synthesis of clopidogrel analogues and their anti-platelet aggregation activities","volume":"18","author":"Chen","year":"2010","journal-title":"Chin. J. Synth. Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib114","doi-asserted-by":"crossref","first-page":"12562","DOI":"10.1021\/acsomega.8b01476","volume":"3","author":"Bharadwaj","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2021.114035_bib115","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1021\/bc9001689","article-title":"PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors","volume":"20","author":"Kim","year":"2009","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejmech.2021.114035_bib116","first-page":"1683","article-title":"Synthesis of diosgenin derivatives and their antithrombotic activity (II)","volume":"42","author":"Fu","year":"2011","journal-title":"Chin. Tradit. Herb. Drugs"},{"key":"10.1016\/j.ejmech.2021.114035_bib117","first-page":"46","article-title":"Synthesis of diosgenin derivatives and their antithrombotic activity","volume":"26","author":"Fu","year":"2011","journal-title":"Drugs & Clinic"},{"key":"10.1016\/j.ejmech.2021.114035_bib118","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.carbpol.2017.12.018","article-title":"2,3-di-o-sulfo glucuronic acid: an unmodified and unusual residue in a highly sulfated chondroitin sulfate from Litopenaeus vannamei","volume":"183","author":"Cavalcante","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejmech.2021.114035_bib119","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/jcbfm.2009.272","article-title":"A\u00a0novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates","volume":"30","author":"Izuhara","year":"2010","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.ejmech.2021.114035_bib120","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1016\/j.bmcl.2016.08.061","article-title":"A\u00a0novel lead of p-selectin inhibitor: discovery, synthesis, bioassays and action mechanism","volume":"26","author":"Wu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114035_bib121","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.carbpol.2015.06.069","article-title":"Synthesis of fibrinolytic active silver nanoparticle using wheat bran xylan as a reducing and stabilizing agent","volume":"132","author":"Harish","year":"2015","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejmech.2021.114035_bib122","first-page":"126","article-title":"Alkaline extraction of xylan from agricultural waste, for the cost effective production of xylooligosaccharides, using thermoalkaline xylanase of thermophilic anoxybacillus sp. Ip-C","volume":"1","author":"Hauli","year":"2013","journal-title":"Int. j. Pure App. Biosci."},{"key":"10.1016\/j.ejmech.2021.114035_bib123","first-page":"259","article-title":"Interpretation of report on cardiovascular diseases in China (2015)","volume":"21","author":"Sui","year":"2016","journal-title":"Chin. J. Cardiovasc. Med."},{"key":"10.1016\/j.ejmech.2021.114035_bib124","first-page":"104","article-title":"Research progress of targeted antithrombotic drugs","volume":"13","author":"Meng","year":"2016","journal-title":"J.\u00a0North Pharm."},{"key":"10.1016\/j.ejmech.2021.114035_bib125","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1055\/s-2000-9802","article-title":"Pathogenesis of a bleeding disorder characterized by platelet unresponsiveness to thromboxane A2","volume":"26","author":"Fuse","year":"2000","journal-title":"Semin. Thromb. Hemost."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:34:23Z","timestamp":1759329263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421008849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":125,"alternative-id":["S0223523421008849"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114035","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114035"}}